The Clorox Company

A DCF analysis estimates Clorox's intrinsic value at approximately $165 per share, roughly 41.5% above its current price, suggesting the market is overly discounting the company's long-term cash flow generation despite near-term cost headwinds. The stock screens as undervalued across five out of six valuation metrics.

Clorox slashed its fiscal 2026 outlook as higher manufacturing and logistics costs, combined with dilution from the GOJO acquisition, continue to compress margins and weigh on sales. Goldman Sachs maintained a sell rating with a $77 price target, reflecting skepticism about near-term margin recovery.

Value-focused and income investors view the GOJO acquisition as a strategic expansion into professional and health-adjacent markets, consistent with Clorox's track record of building essential consumer brands and maintaining dividend growth over more than five decades.

The GOJO acquisition is generating meaningful earnings dilution and adding to cost burdens, contributing directly to Clorox's decision to lower its fiscal 2026 guidance. Barclays set an underweight rating with an $85 price target, citing the deal as a drag on near-term financial performance.

Clorox trades at a P/E of approximately 15.4x, well below the household products industry average of 17.8x and a peer group average of 27.4x. A tailored fair P/E of 18.0x suggests the current price already embeds overly cautious expectations, making the stock an attractive entry point for long-term investors.

Forecasted EPS for next year stands at $5.17, down sharply from $6.56 the prior year, reflecting a deteriorating earnings trajectory. With the stock already down over 36% in the past year and analyst consensus averaging a Reduce rating, the earnings reset may signal structural weakness rather than a temporary discount.